R&D Threats impacting the pharmaceutical industry in 2024 As we approach 2024, what will the next 12 months have in store for pharma?
News Regenxbio, Solid report data with Duchenne gene therapies Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta's Elevidys.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
